SCHEMBL922232

SCHEMBL922232

CC(C)(C)OC(=O)n1nc(N)c2cc(C#N)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.41
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRA6 Q16445 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.39
GPR119 Q8TDV5 6/20 0.38
GUCY1A1 Q02108 1/20 0.37
GUCY1B1 Q02153 1/20 0.37
KCNH2 Q12809 1/20 0.37
NR1H2 P55055 1/20 0.36
EGLN2 Q96KS0 1/20 0.36
PDGFRA P16234 1/20 0.35
CDK5 Q00535 1/20 0.35
TYRO3 Q06418 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
ELANE P08246 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4781102 0.86 GABRA1 (0.41) MAP2K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL2861383 0.85 GABRA1 (0.40) MAP2K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL11754180 0.84 ELANE (0.47) GUCY1A1GUCY1B1KCNH2ELANE
SCHEMBL660243 0.83 MAP2K4 (0.45) MAP2K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL13748554 0.82 MAP2K4 (0.44) MAP2K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL29439761 0.81 PDGFRA (0.52) MAP2K4GABRG2GABRB3GABRA5PDGFRA
SCHEMBL1943689 0.81 PDGFRA (0.52) MAP2K4GABRG2GABRB3GABRA5PDGFRA
SCHEMBL16800567 0.81 MAP2K4 (0.46) MAP2K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL4212522 0.81 GUCY1A1 (0.36) GABRA1GABRG2GABRB3GABRA5GABRA2
SCHEMBL924609 0.79 NR1H2 (0.44) MAP2K4GABRG2GABRB3GABRA5NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232620-A1 3-Aminoindazoles SGK3, SGK1, SGK2 MAP2K4 633/4885GABRA1 2069/4885GABRG2 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.